Ajay Kumar Singh Rawat
Maharishi School of Pharmaceutical Sciences, Maharishi University of Information Technology, Lucknow, Uttar Pradesh, 226013, India

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

Formulation, optimization and characterization of apremilast-loaded nanosponges for potential topical wound management applications Purnima Rai; Ajay Kumar Singh Rawat
Journal of Applied Pharmaceutical Research Vol. 14 No. 4 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i4.2153

Abstract

Background: Topical drug delivery systems provide site-specific therapy with reduced systemic exposure. Nanosponges have emerged as promising carriers owing to their porous structure, enabling improved drug stability, bioavailability, and sustained release. Apremilast, a phosphodiesterase-4 (PDE4) inhibitor with anti-inflammatory activity, has potential for topical wound management when formulated as a controlled-release delivery system. Methods: Apremilast-loaded nanosponges were prepared by the emulsion solvent diffusion method using Ethyl Cellulose (EC) and Polyvinyl Alcohol (PVA). A 3² factorial design was used to optimize the EC: PVA ratio and sonication time. Formulations were evaluated for particle size, entrapment efficiency, zeta potential, in vitro drug release, and surface morphology. Characterization included UV spectroscopy, FTIR, XRD, DSC, and SEM. Drug release kinetics were analyzed using mathematical models. Results: Preformulation studies confirmed drug purity and compatibility with excipients. The optimized formulation (NS8) exhibited a particle size of 213.85 nm, an entrapment efficiency of 82.75%, a zeta potential of −33.3 mV, and a sustained drug release of 95.85% over 24 h. SEM revealed spherical porous nanosponges, while FTIR, XRD, and DSC confirmed drug integrity and formulation stability. Response surface analysis demonstrated significant effects of formulation variables on performance. Drug release followed the Higuchi model (R² = 0.987), and the Korsmeyer–Peppas exponent (n = 0.58) indicated anomalous non-Fickian diffusion. Conclusion: Apremilast-loaded nanosponges demonstrated sustained drug release, excellent stability, and favorable physicochemical characteristics, indicating their potential as an effective topical delivery system for wound management. Further ex vivo, in vivo, and clinical studies are required to confirm therapeutic efficacy and safety.
Quality by design based optimization and physicochemical characterization of flucytosine nanoemulsion Rajat Srivastava; Ajay Kumar Singh Rawat
Journal of Applied Pharmaceutical Research Vol. 14 No. 4 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i4.2247

Abstract

Background: The rise of pathogenic fungi capable of infecting people is a major public health problem. Flucytosine is an effective antifungal agent, but its clinical use is constrained by rapid clearance and dose-related adverse effects. Nanoemulsion-based systems offer a promising strategy for drug delivery and therapeutic performance. The objective of this work was to develop and optimize a flucytosine-loaded nanoemulsion using a Quality by Design (QbD) approach based on the Box-Behnken design, and to evaluate its physicochemical characteristics. Methodology: A Box-Behnken design (BBD) was used to optimize formulation factors, including lipid concentration, Smix (surfactant-to-cosurfactant) ratio, and homogenization time, using high-speed homogenization. The impacts on particle size, polydispersity index, and entrapment efficiency (EE) were investigated. UV-visible spectroscopy, Fourier-transform infrared spectroscopy (FTIR), and X-ray diffraction (XRD) were used to assess the compatibility and stability of the improved formulation (F11) with the chosen excipients. Results and Discussion: The optimized formulation (F11) had a particle size of 318.18 nm and a PDI of 0.136, a zeta potential of -22.2 mV, and high entrapment efficiency (96.36%), indicating good stability and uniformity. Preformulation and compatibility studies confirmed the absence of drug-excipient interactions. Statistical analysis demonstrated that formulation variables significantly influenced critical quality attributes. Conclusion: The study demonstrates that QbD-driven optimization can successfully develop a stable and efficient flucytosine nanoemulsion with enhanced drug-loading capacity and potential to improve antifungal therapy. However, further studies, including in vitro drug release, in vivo evaluation, long-term stability, and clinical validation, are required to confirm its performance in drug delivery applications.
Nanosponge-facilitated topical administration of apremilast improves wound healing via prolonged release and diminished inflammation Purnima Rai; Ajay Kumar Singh Rawat
Journal of Applied Pharmaceutical Research Vol. 14 No. 5 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i5.2277

Abstract

Background: Apremilast, a phosphodiesterase-4 inhibitor with anti-inflammatory activity, has potential for wound management; however, poor aqueous solubility and limited topical retention may reduce its effectiveness. Nanosponge-based gels may enhance local retention and sustained drug release. Methodology: Nine nanosponge gel formulations (NSG1–NSG9) were prepared using varying concentrations of Carbopol 934 and propylene glycol. Formulations were evaluated for homogeneity, pH, viscosity, spreadability, extrudability, and drug content. In vitro release was assessed for 24 h using a Franz diffusion cell. The optimized formulation was evaluated for dermal irritation and wound-healing efficacy in Wistar rats using an excision wound model. Histopathological examination and a three-month stability study were also performed. Results and Discussion: NSG7 showed optimal characteristics, with pH 5.92 ± 0.04, viscosity 9,850 ± 145 cP, spreadability 4.8 ± 0.12 g·cm/s, extrudability 440 ± 8 g, and drug content 99.2 ± 0.4%. Drug release reached 82.19 ± 6.80% at 12 h and 94.97 ± 4.91% at 24 h. NSG7 was non-irritant and enhanced wound contraction, epithelialization, collagen deposition, and tissue remodeling compared with untreated and conventional apremilast gel groups. However, the absence of a drug-free Carbopol 934 vehicle control prevented separation of vehicle- related effects from those of the drug-loaded nanosponge system. Conclusion: NSG7 demonstrated favorable sustained drug release, dermal safety, and promising wound-healing activity. The observed in vivo benefits may reflect combined effects of apremilast- loaded nanosponges. Further studies incorporating a vehicle control and extended preclinical and clinical evaluation are warranted.